Close Menu

tuberculosis

In Genome Biology this week: analysis of tuberculosis samples from the 1600s, tool to detect variants affecting RNA-binding protein activity, and more.

The money will be used for research and development, building a clinical laboratory network, and seeking regulatory approval.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.

In PLOS this week: Aedes aegypti and Ae. albopictus mosquito population genomics, strategies to profile hepatitis viruses, and more.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

In PLOS this week: sequencing-based way to uncover drug resistance in tuberculosis bacteria, genetic population structure of mosquito vectors, and more.

The sequencing-based test is designed to detect mutations that cause resistance to 15 first- and second-line antibiotics used to treat tuberculosis.

The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.

The company has been collecting data on broader applicability of its electric field chip technology for potential use in DNA, RNA, exosome, and protein applications.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.